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To the Editor: A 61-year-old man underwent trans-
urethral prostate resection in Vancouver, British Columbia, 
in January 2016. On postoperative day 1, he was febrile 
(39.1°C) and had leukocytosis (12.7 × 109 cells/L). Blood 
and urine cultures were ordered on postoperative day 2, and 
ceftriaxone was started. On postoperative day 3, urine culture 
grew Escherichia coli (>100 million CFU/L). Susceptibility 
testing (VITEK2, bioMérieux, Quebec, Canada) indicated 
a possible extended-spectrum β-lactamase producer and 
showed resistance to ampicillin, cefazolin, ceftriaxone, gen-
tamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole; 
intermediate resistance to tobramycin; and susceptibility to 
amoxicillin/clavulanate, piperacillin/tazobactam, ertapenem, 
meropenem, and nitrofurantoin. Treatment was switched to 
amoxicillin/clavulanate. The urinary catheter was removed 
48 hours later. The patient was discharged on postoperative 
day 5 and completed 14 days of oral amoxicillin/clavulanate. 
Blood cultures were negative after 7 days’ incubation.
The E. coli cultured from the patient underwent further 
testing and grew in equal amounts on Columbia Colistin-
Nalidixic acid Agar (CNA) with 5% sheep blood and Co-
lumbia agar with 5% sheep blood (OXOID, Ontario, Cana-
da). This result was brought to the attention of the hospital’s 
medical microbiologist. A colistin Etest (bioMérieux, Que-
bec, Canada) showed a MIC of 3 µg/mL; EUCAST defines 
colistin resistance as >2 µg/mL for Enterobacteriaceae (1).
A real-time PCR to detect the mobile colistin resis-
tance (mcr-1) gene was developed at the Provincial Public 
Health Laboratory by using primers MCR-1F (5′-CATC-
GCTCAAAGTATCCAGTGG-3′), MCR-1R (5′-CCATG-
TAGATAGACACCGTTCTCAC-3′), and probe MCR-1P 
(5′-Cy5-TGCAGACGCACAGCAATGCCTATGAT-
TAO-3′) with TaqMan Fast Advanced Master Mix (Life Tech-
nologies, Burlington, Ontario, Canada), on an ABI 7500 FAST 
thermocycler (Applied Biosystems, Foster City, CA) by using 
manufacturer’s’ recommended conditions. The mcr-1 gene 
was confirmed by Sanger sequencing by using previously de-
scribed oligonucleotides (2). The isolate was also PCR-positive 
for a blaCTX-M gene. The strain was sequenced by using MiSeq 
(Illumina, Victoria, British Columbia, Canada), and predicted 
to be sequence type 3944 based on multilocus sequence typ-
ing databases (http://github.com/tseemann/mlst; http://mlst.
warwick.ac.uk/mlst/dbs/Ecoli) and serotype O159:H4 (3). 
Sequence type 3944 does not belong to any clonal groups; 1 
isolate from Asia is in the MLST database. Abricate (http://
github.com/tseemann/abricate) and PlasmidFinder (4) were 
used to query the SPAdes-assembled genome (5). Results 
showed that this isolate carries 3 plasmids that have IncR, In-
cFIA/HI, and IncI2 replicons. The mcr-1 gene was found on a 
60,599-nt contig with the IncI2 replicon; this contig is ≈87% 
identical to pHNSHP45 (Figure) (2). The blaCTX-M-27 gene was 
found on the same contig as the IncFIA/HI replicon, and no 
resistance genes were found with the IncR replicon.
At the time of mcr-1 detection, the patient and all oth-
er patients who shared a hospital room with this patient, 
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all for <24 h, had been discharged. According to a public 
health representative, and on the basis of the limited expo-
sure duration of roommates, discharged roommates were 
not screened. The patient improved clinically, so no chang-
es to therapy were indicated.
The patient had traveled to China in November 2015 
for 2 weeks, where he required catheterization in a hospi-
tal emergency department in Zhejiang Province for acute 
urinary retention. He experienced acute urinary retention 
and fever 6 days after catheter removal, requiring another 
catheter insertion and 3 days of intravenous antimicrobi-
al drugs in Guangdong Province. He denied contact with 
farm animals, live poultry markets, or undercooked meat. 
On return to Canada, obstructive urinary tract symptoms 
persisted, requiring 5 emergency department visits before 
prostate resection. 
Colistin is a last-resort antibacterial drug because of its 
toxic effects and is increasingly used for treating carbapen-
em-resistant Enterobacteriaceae (CRE). Plasmid-mediated 
resistance genes have been described in agricultural animals 
and meat, as well as in humans. Initial reports described the 
mcr-1 gene in China and Southeast Asia (2,7). Retrospec-
tive reviews have detected mcr-1 in Enterobacteriaceae 
from Europe, South America, Africa, and Japan (7).
Unlike laboratory detection of CRE, where screening 
media and automated susceptibility panels were available, 
no commercial screening media exist for mcr-1. MIC test-
ing is only recommended for Enterobacteriaceae resistant 
to all other antimicrobial classes, and molecular testing may 
not be accessible. Furthermore, some Enterobacteriaceae 
are intrinsically resistant to colistin. Only Etest (http://etest.
net/) could be performed in our laboratory, which is a limi-
tation that may underestimate the actual MIC (8). However, 
the reference broth microdilution method is unavailable to 
most clinical laboratories. This isolate was identified by a 
technologist who recognized heavy growth of E. coli on a 
CNA plate, an unusual occurrence because CNA plates are 
used for the isolation of gram-positive bacteria while inhib-
iting gram-negative bacteria. Despite serendipitously iden-
tifying mcr-1 on the CNA, this method is an inadequate for 
detection of mcr-1.
Retrospective screening has identified mcr-1 isolates 
in Canada (9). However, we describe a prospectively iden-
tified patient in Canada with E. coli harboring the mcr-1 
gene. The patient’s travel history suggested that acquisition 
occurred in China, although only 1% of inpatients with in-
fection in Guangdong/Zhejiang Provinces harbor mcr-1 (2).
Limited laboratory screening procedures have impli-
cations for laboratories and public health. Routine colistin 
testing for Enterobacteriaceae would be costly and low-
yield; however, without such testing, the real prevalence of 
mcr-1 will be underestimated. A coordinated approach to 
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Figure. The mcr-1–containing 
contig from Escherichia 
coli isolated from a traveler 
returning to Canada from 
China compared to pHNSHP45 
plasmid. BRIG (6) was used to 
generate a visual representation 
of the 60,599-nt contig 
assembled from the sequencing 
of the mcr-1–positive isolate to 
pHNSHP45 (2). Coding regions 
are represented in the inner 
ring; the mcr-1–containing 
contig is represented in the 
outer ring. The mcr-1 gene is 
indicated in a black segment in 
the inner ring.
the prevention of mcr-1 dissemination is needed, particu-
larly to prevent the proliferation of an organism harboring 
a plasmid with mcr-1 and a carbapenemase (10).
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To the Editor: Carbapenems, antimicrobial drugs 
of last resort, are recommended only for severe commu-
nity- and healthcare-associated multidrug-resistant bacte-
rial infections. In Canada, carbapenem-resistant infection 
rates in hospitals remained low (<0.25 cases/1,000 patient 
admissions) over 5 years’ (2009–2014) surveillance (1). 
Carbapenemase-producing bacteria have rarely been de-
tected in the food chain in industrialized countries. Howev-
er, carbapenemase genes were detected in bacteria isolated 
from produce in Switzerland (2) and seafood in Canada (3); 
implicated food items originated from Southeast Asia. We 
conducted targeted sampling to assess, using selective me-
dia, the occurrence of carbapenem-resistant Enterobacte-
riaceae in imported seafood products sold in Canada.
For testing, we selected 1,328 retail seafood samples: 
928 were imported fresh and frozen raw shrimp collected 
during 2011–2015 by CIPARS (the Canadian Integrated 
Program for Antimicrobial Resistance Surveillance), and 
400 comprised an assortment of imported niche-market 
fresh and frozen raw seafood collected specifically for 
this study during January–April 2015. Product informa-
tion and origin country were recorded for each sample. 
We used chromID CARBA agar (bioMérieux, St. Laurent, 
QC, Canada) to select putative colonies. To determine car-
bapenemase production on nonsusceptible (zone of inhibi-
tion <25 mm) isolates, we used disk diffusion susceptibility 
to ertapenem and meropenem (10 μg each) and the Carba 
NP test as previously described (4). Isolates were identi-
fied to species using matrix-assisted laser desorption/ion-
ization time-of-flight mass spectrometry (Bruker Dalton-
ics Ltd, Milton, ON, Canada) and tested for susceptibility 
using the Sensititre Complete Automated System with the 
Sensititre NARMS Gram Negative Plate (CMV3AGNF) 
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